Read Summary

Patients with fast-growing non-pancreatic neuroendocrine tumors may respond to combination therapy with ipilimumab plus nivolumab, according to findings within the Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART) trial.
Reuters Health Information

Print Friendly, PDF & Email